Drug Profile
Research programme: tau inhibitor - APRINOIA Therapeutics
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator APRINOIA Therapeutics
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Neurodegenerative disorders
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for research development in Alzheimer's-disease in Taiwan
- 28 Oct 2021 No recent reports of development identified for research development in Neurodegenerative-disorders in Taiwan
- 29 Dec 2020 APRINOIA Therapeutics in-licenses AI-powered system from InSilico Medicine